Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 15OTHER 8NIH 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lung Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Neoplasm Metastasis 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Prostate Cancer Metastatic 1Oropharyngeal Neoplasms 1Oligometastatic Squamous Cell Carcinoma of the Head and Neck 1Neoplasm, Residual 1Mouth Neoplasms 1Mesothelioma 1Melanoma 1Leukemia, Myeloid, Chronic-Phase 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Hodgkin Disease 1Gallbladder Neoplasms 1Colorectal Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1Carcinoma 1Breast Neoplasms 1Biliary Tract Neoplasms 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Gemcitabine 10Cisplatin 7S 1 (combination) 6titanium silicide 2Oxaliplatin 2spartalizumab 1pembrolizumab 1pamiparib 1atezolizumab 1World Health Organization oral rehydration solution 1Temozolomide 1Paclitaxel 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Biliary Tract Neoplasms × pembrolizumab × Clear all
NCT03260712 2023-11-03

Pembrolizumab in Biliary Tract Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
50 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡